Wuxi Biologics: 2025 Net Profit Growth of 46.3% to RMB 4.908 Billion, Achieving Significant Growth in Both Biologics Drug and XDC Business Segments

LightningPacketLoss · 2026-03-24T19:29:08+00:00

Wuxi AppTec Biologics released its full-year results for the year ended December 31, 2025, with revenues of 21.79 billion yuan, representing a year-on-year increase of 16.7%. The company achieved gross profit of 10.019 billion yuan, with gross margin improving to 46.0%. Net profit attributable to shareholders increased by 46.3%. The company added 209 new projects, demonstrating significant business growth, particularly with strong performance in the biologics drug and XDC segments.

LightningPacketLoss

2026-03-24 19:29:08

Abstract generation in progress

On March 24, WuXi Biologics announced its full-year financial results for the period ending December 31, 2025. The company’s revenue for 2025 was 21.79 billion yuan, a 16.7% increase year-over-year; gross profit was 10.019 billion yuan, up 30.9%, with gross profit margin rising to 46.0%; net profit attributable to shareholders was 4.908 billion yuan, a 46.3% increase.

In the management discussion and analysis section, the company mentioned that significant business growth was driven by an integrated CRDMO platform and the “Follow and Win with Molecules” strategy, adding 209 new integrated projects, bringing the total to 945. Clinical-stage and commercial manufacturing projects also increased to 74 and 25, respectively.

In the notes to the financial statements, cost of sales increased from 11.025 billion yuan to 11.772 billion yuan, a 6.8% rise. Overall, the company achieved notable growth in both its biopharmaceutical and XDC segments, with external sales of 15.89 billion yuan for biopharmaceuticals and 5.9 billion yuan for XDC, demonstrating strong market performance and competitiveness.

(WuXi Biologics Announcement)

(Edited by: Yang Yan, Lin Chen)

Keywords: Healthcare

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.